Edition:
United States

Key Developments: Neuralstem Inc (CUR.PH)

CUR.PH on Philadelphia Stock Exchange

0.35USD
27 May 2016
Change (% chg)

$-0.01 (-3.42%)
Prev Close
$0.36
Open
$0.35
Day's High
$0.35
Day's Low
$0.34
Volume
800
Avg. Vol
529
52-wk High
$2.35
52-wk Low
$0.31

Latest Key Developments (Source: Significant Developments)

Neuralstem announces corporate reorganization
Friday, 20 May 2016 08:36am EDT 

Neuralstem Inc : Neuralstem announces plan of reorganization to further align business with strategic intent . Corporate reorganization to further align company's resources on advancing NSI-189 Neurogenic small molecule program . Says corporate reorganization includes a workforce reduction across all divisions . Reorganization to align resources on advancing NSI-189 neurogenic small molecule program, currently in a phase 2 clinical trial .Reorganization also to continue to pursue collaborations for NSI-566 stem cell therapy program that will expedite clinical development.  Full Article

Neuralstem entered into agreement to sell 2.7 mln shares
Thursday, 12 May 2016 05:16pm EDT 

Neuralstem Inc : Entered into agreement to sell 2.7 million shares of stock and warrants to purchase 2.7 million shares of common stock in private placement .Securities are being sold in private offering at a price of $0.40 per one share of common stock and one common stock purchase warrant.  Full Article

Neuralstem says first patient enrolled in Phase 2 trial in major depressive disorder
Thursday, 12 May 2016 09:43am EDT 

Neuralstem Inc - : Neuralstem expects to report results in second half of 2017 . Neuralstem Inc says there were no significant adverse effects in phase 1b safety trial data in patients with mdd .Neuralstem announces first patient enrolled in phase 2 clinical trial in major depressive disorder.  Full Article

Neuralstem posts Q1 loss per share $0.07
Monday, 9 May 2016 10:30am EDT 

Neuralstem Inc : Q1 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S . Neuralstem reports fiscal first quarter 2016 results and business update .Q1 loss per share $0.07.  Full Article

Neuralstem Inc prices underwritten public offering of securities
Tuesday, 3 May 2016 08:22am EDT 

Neuralstem Inc:Pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $0.40 per share.Offering is expected to close on May 6.Gross proceeds of the offering are expected to be approximately $8 million.Intends to use the net proceeds from this underwritten offering to fund regulatory, pre-clinical and clinical activities and general corporate purposes, including working capital and the repayment of debt.  Full Article

Neuralstem Inc appoints Richard Daly as President and CEO
Tuesday, 16 Feb 2016 07:35am EST 

Neuralstem Inc:Appoints Richard Daly as president and chief executive officer.Daly succeeds Richard Garr as CEO.Says daly is also being appointed to the company's board of directors.  Full Article

Neuralstem Inc provides phase II update on als cell therapy at American neurological association annual meeting
Tuesday, 29 Sep 2015 08:05am EDT 

Neuralstem Inc:Investigator provides phase II update on als cell therapy at American neurological association annual meeting.Says there appeared to be no acceleration in disease progression due to the therapeutic intervention.Data showed that intraspinal transplantation of the cells was safe and well-tolerated throughout the escalating doses.  Full Article

Neuralstem appoints Jonathan Lloyd Jones as chief financial officer
Wednesday, 6 May 2015 07:31am EDT 

Neuralstem Inc:Appointed Jonathan Lloyd Jones as chief financial officer effective May 18.  Full Article

Neuralstem, Inc announces topline results of Phase II ALS Trial
Thursday, 12 Mar 2015 06:50am EDT 

Neuralstem, Inc:Says top line data from Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for treatment of amyotrophic lateral sclerosis (ALS).Maximum tolerated dose of 16 mln transplanted cells and surgery was well tolerated.Secondary efficacy endpoints at nine months post-surgery indicate 47 pct response rate to stem cell treatment.As measured by either near-zero slope of decline or positive slope of ALSFRS score in seven out of 15 patients and by either a near-zero decline, or positive strengthening, of grip strength in seven out of 15 patients.Grip strength is an indicator of direct muscle strength of lower arm and ALSFRS is standard clinical test used to evaluate functional status of ALS patients.Average ALSFRS score for responders at 9 months after treatment was 37 and non-responders scored an average of 14 and scores represent 93 pct, versus 35 pct of baseline score retained respectively.As measured by an average slope of decline of ALSFRS, responders' disease progression was -0.007 point per day, while non-responders' disease progression was -0.1 per day, which was again statistically significant.Trial met it's primary safety endpoints.Both surgery and cells were well-tolerated, with one patient experiencing a surgical serious adverse event.  Full Article

Neuralstem Inc final phase I depression data Presented at American Society Of Clinical Psychopharmacology
Wednesday, 18 Jun 2014 09:15am EDT 

Neuralstem Inc:Final data from Neuralstem NSI-189 Phase Ib study in major depressive disorder (MDD) was presented at American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida.NSI-189 is Neuralstem's first-in-class, lead neurogenic small molecule compound, shown to promote neurogenesis in vitro.In animal studies, NSI-189 resulted in 20 pct increase in hippocampal volume.Specifically, a large effect was seen in all four scales employed in the study that are commonly used to assess clinical levels of depression and improvement.Says CGI-I (Clinical Global Impression Improvement); MADRS (Montgomery-Asberg Depression Scale), SDQ (Symptoms of Depression Questionnaire) and CPFQ (Massachusetts General Cognitive and Physical Functioning Questionnaire).In particular, the Symptoms of Depression Questionnaire (SDQ) showed 0.02 p value at day 28 of dosing, with large effect size (Cohen's d = 0.90), and 0.03 p value at day 84, 8 weeks after cessation of drug administration, also with large effect size.  Full Article

BRIEF-Neuralstem announces corporate reorganization

* Neuralstem announces plan of reorganization to further align business with strategic intent